Clinical Trial Finder: Recruiting Trials

At Bristol Myers Squibb, we are driven by the discovery of science that will transform the lives of patients, and our therapeutic pipeline has the potential to do just that.
Because of our focus on patients, we want to make it easier to find trials relevant to them. Please explore our recruiting and not yet recruiting pipeline trials below to help identify a trial that might be right for your patient.

The safety and efficacy of the agents and/or uses under investigation have not been established. There is no guarantee that the agents will receive health authority approval or become commercially available in any country for the uses being investigated.

107 Trials Across 6 Therapeutic Areas

Use the filters below to view trials in specific therapeutic areas or disease areas within the therapeutic areas. You can also filter by trial phase and status. Multiple filters may be added at once. Trials are listed alphabetically and by therapeutic area.

Recruiting status legend

  • Recruiting Trials
  • Not Yet Recruiting Trials
  • Various (Select “View trials” to see status for each trial).
Filter by:
  • Therapeutic Area
    close
    Filter by Therapeutic Area:
    Back to all Therapeutic Areas

    Cardiovascular

    Clear all

    Fibrotic Diseases

    Clear all

    Hematology

    Clear all

    Immunology

    Clear all

    Neuroscience

    Clear all

    Solid Tumors

    Clear all
  • Trial Phase
    close
    Filter by Trial Phase:
  • Trial Status
    close
    Filter by Trial Status:

    *Various (Select “View Trial” to see status for each trial).

Clear all
  • Cardiovascular
  • Heart Failure
  • Pediatric Heart Disease
  • Thrombotic Disorders
  • VTE prevention in pediatrics with ALL
  • Fibrotic Diseases
  • Fibrosis
  • Nonalcoholic Steatohepatitis
  • Pulmonary Fibrosis
  • Hematology
  • Acute Lymphocytic Leukemia
  • Acute Myeloid Leukemia
  • Beta-Thalassemia
  • Chronic Lymphocytic Leukemia
  • Chronic Myelogenous Leukemia
  • Hematologic Malignancies
  • Lymphoma
  • Myelodysplastic Syndromes
  • Multiple Myeloma
  • Myelofibrosis
  • Immunology
  • Autoimmune Disease
  • Crohn's Disease
  • Eosinophilic Esophagitis
  • Idiopathic Inflammatory Myopathy
  • Lupus Nephritis
  • Multiple Sclerosis
  • Psoriasis
  • Psoriatic Arthritis
  • Renal Transplant
  • Rheumatoid Arthritis
  • Sjögren's Syndrome
  • Systemic Lupus Erythematosus
  • Ulcerative Colitis
  • Neuroscience
  • Neuroscience (General)
  • Solid Tumors
  • Bladder
  • Breast
  • Colorectal
  • Esophageal, Gastroesophageal
  • Gastric
  • Glioblastoma
  • Head & Neck
  • Hepatocellular Carcinoma
  • Lung Cancer
  • Mesothelioma
  • Melanoma
  • Ovarian
  • Pan-Tumor TMB High
  • Pancreatic Cancer
  • Pediatric
  • Prostate
  • Solid Tumors (General)
  • Renal Cell Carcinoma
  • Not found

Heart Failure

Expand All Displaying 5 of 11

Heart Failure

No trials are available at this time. Check back for updates.

Pediatric Heart Disease

apixaban
factor Xa inhibitor
Area of Research: Pediatric Heart Disease
Phase 2
Expand All Displaying 5 of 11

Pediatric Heart Disease

No trials are available at this time. Check back for updates.

Thrombotic Disorders

BMS-986177
factor XIa inhibitor
Area of Research: Thrombotic Disorders
Phase 2
BMS-986177 + aspirin + clopidogrel
factor XIa inhibitor + NSAID + antiplatelet
Area of Research: Thrombotic Disorders
Phase 2
Expand All Displaying 5 of 11

Thrombotic Disorders

No trials are available at this time. Check back for updates.

VTE prevention in pediatrics with ALL

apixaban
factor Xa inhibitor
Area of Research: VTE prevention in pediatrics with ALL
Phase 3
Expand All Displaying 5 of 11

VTE prevention in pediatrics with ALL

No trials are available at this time. Check back for updates.

Fibrosis

Expand All Displaying 5 of 11

Fibrosis

No trials are available at this time. Check back for updates.

Nonalcoholic Steatohepatitis

BMS-986263
HSP47
Area of Research: Compensated Cirrhosis from NASH
Phase 2
CC-90001
JNK inhibitor
Area of Research: NASH and Stage 3 /4 Fibrosis
Phase 2
Expand All Displaying 5 of 11

Nonalcoholic Steatohepatitis

No trials are available at this time. Check back for updates.

Pulmonary Fibrosis

BMS-986278
LPA1 antagonist
Area of Research: Pulmonary Fibrosis
Phase 2
CC-90001
JNK inhibitor
Area of Research: Pulmonary Fibrosis
Phase 2
Expand All Displaying 5 of 11

Pulmonary Fibrosis

No trials are available at this time. Check back for updates.

Acute Lymphocytic Leukemia

Expand All Displaying 5 of 11

Acute Lymphocytic Leukemia

No trials are available at this time. Check back for updates.

Acute Myeloid Leukemia

BMS-90011
LSD1 Inhibitor
Area of Research: R/R and Treatment-Naïve AML
Phase 1/2
CC-90009 + azacitidine + BH3-mimetic
GSPT1 CELMoD + BH3-mimetic + HMA
Area of Research: R/R AML
Phase 1/2
CC-90009 + FLT3/AXL inhibitor
GSPT1 CELMoD + FLT3/AXL inhibitor
Area of Research: R/R AML
Phase 1/2
CC-90009
GSPT1 immunomodulatory agent
Area of Research: R/R AML
Phase 1
Expand All Displaying 5 of 11

Acute Myeloid Leukemia

No trials are available at this time. Check back for updates.

Beta-Thalassemia

luspatercept-aamt
erythroid maturation agent
Area of Research: Long-term safety
Phase 3
luspatercept-aamt
erythroid maturation agent
Area of Research: Non-Transfusion-Dependent
Phase 2
Expand All Displaying 5 of 11

Beta-Thalassemia

No trials are available at this time. Check back for updates.

Chronic Lymphocytic Leukemia

liso-cel ± BTK inhibitor
CD-19 CAR T ± BTK inhibitor
Area of Research: R/R CLL
Phase 1/2
Expand All Displaying 5 of 11

Chronic Lymphocytic Leukemia

No trials are available at this time. Check back for updates.

Chronic Myelogenous Leukemia

Expand All Displaying 5 of 11

Chronic Myelogenous Leukemia

No trials are available at this time. Check back for updates.

Hematologic Malignancies

nivolumab + bempegaldesleukin
anti–PD-1 + CD-122-preferential IL-2 pathway agonist
Area of Research: Recurrent or Treatment-Resistant
Phase 1/2
Expand All Displaying 5 of 11

Hematologic Malignancies

No trials are available at this time. Check back for updates.

Lymphoma

liso-cel + anti–PD-1
CD-19 CAR T + anti–PD-1
Area of Research: FL / MZL: 3L+
Phase 1/3
liso-cel + BTK inhibitor
CD-19 CAR T + BTK inhibitor
Area of Research: DLBCL: 3L
Phase 1/2
nivolumab + anti–CD30 (ADC)
anti–PD-1 + anti–CD-30 (ADC)
Area of Research: Children, adolescents, and young adults with 2L cHL
Phase 2
liso-cel ± BTK inhibitor
CD-19 CAR T ± BTK inhibitor
Area of Research: CLL: 3L+
Phase 1/2
liso-cel + immunomodulatory agent
CD-19 CAR T + immunomodulatory agent
Area of Research: DLBCL: 3L
Phase 1/2
liso-cel + immunomodulatory agent
CD-19 CAR T + immunomodulatory agent
Area of Research: FL / MZL: 3L+
Phase 1/2
liso-cel
CD-19 CAR T
Area of Research: DLBCL: 3L
Phase 2
liso-cel + chemo
CD-19 CAR T + chemo
Area of Research: Pediatric B-Cell ALL: 2L+
Phase 1/2
liso-cel + anti–PD-1
CD-19 CAR T + anti–PD-1
Area of Research: DLBCL: 3L
Phase 1/2
liso-cel + chemo
CD-19 CAR T
Area of Research: FL / MZL: 3L+
Phase 2
liso-cel + BTK inhibitor
CD-19 CAR T + BTK inhibitor
Area of Research: FL / MZL: 3L+
Phase 1/2
CC-97540
CD-19 NEX T
Area of Research: DLBCL: 3L
Phase 1
CC-99282 + anti–CD-20
A/I immunomodulatory agent ± anti–CD-20
Area of Research: R/R NHL
Phase 1
liso-cel
CD-19 CAR T
Area of Research: MCL: 3L+
Phase 1
iberdomide + anti–CD-20
immunomodulatory agent + anti–CD-20
Area of Research: MCL: 3L+
Phase 1
iberdomide + anti–CD-20
immunomodulatory agent + anti–CD-20
Area of Research: DLBCL TNE: 2L
Phase 1
iberdomide + anti–CD-20
immunomodulatory agent + anti–CD-20
Area of Research: FL / MZL: 3L+
Phase 1
CC-99282 ±anti–CD-20
A/I immunomodulatory agent ± anti–CD-20
Area of Research: R/R NHL
Phase 1
TRPH-222
CD22 ADC (TriPhase)
Area of Research: R/R lymphoma
Phase 1
Expand All Displaying 5 of 11

Lymphoma

No trials are available at this time. Check back for updates.

Multiple Myeloma

ide-cel
BCMA CAR T
Area of Research: R/R MM: 3L-4L
Phase 3
CC-92480 + anti–CD-30
A/I immunomodulatory agent + anti–CD-30 + steroid
Area of Research: R/R MM
Phase 1/2
CC-92480 + proteasome inhibitor + steroid
A/I immunomodulatory agent + proteasome inhibitor + steroid
Area of Research: R/R MM
Phase 1/2
CC-92480 ± steroid
A/I immunomodulatory agent + steroid
Area of Research: R/R MM
Phase 1/2
iberdomide + anti–PD-1 + steroid
immunomodulatory agent + anti–PD-1 + steroid
Area of Research: R/R MM
Phase 1/2
iberdomide + proteasome inhibitor + steroid
immunomodulatory agent + proteasome inhibitor + steroid
Area of Research: R/R MM
Phase 1/2
iberdomide ± steroid
immunomodulatory agent ± steroid
Area of Research: R/R MM
Phase 1/2
ide-cel
BCMA CAR T
Area of Research: R/R MM: 2L
Phase 2
ide-cel
BCMA CAR T
Area of Research: R/R MM: 3L-5L
Phase 2
pomalidomide + steroid ±anti–CD-30
immunomodulatory agent + steroid ± anti–CD-30
Area of Research: R/R MM
Phase 2
CC-93269
BCMA TCE
Area of Research: R/R MM
Phase 1
CC-98633
NEX T BCMA
Area of Research: R/R MM
Phase 1
CC-99712
BCMA ADC
Area of Research: R/R MM
Phase 1
ide-cel
BCMA CAR T
Area of Research: HR NDMM
Phase 1
Expand All Displaying 5 of 11

Multiple Myeloma

No trials are available at this time. Check back for updates.

Myelodysplastic Syndromes

luspatercept-aamt
erythroid maturation agent
Area of Research: ESA Naïve
Phase 3
luspatercept-aamt
erythroid maturation agent
Area of Research: Long-term safety
Phase 3
Expand All Displaying 5 of 11

Myelodysplastic Syndromes

No trials are available at this time. Check back for updates.

Myelofibrosis

luspatercept-aamt
erythroid maturation agent
Area of Research: Long-term safety
Phase 3
fedratinib + luspatercept
JAK2 inhibitor + erythroid maturation agent
Area of Research: Previously treated with ruxolitinib
Phase 3
luspatercept-aamt
erythroid maturation agent
Area of Research: MF anaemia
Phase 2
Expand All Displaying 5 of 11

Myelofibrosis

No trials are available at this time. Check back for updates.

Autoimmune Disease

Expand All Displaying 5 of 11

Autoimmune Disease

No trials are available at this time. Check back for updates.

Crohn’s Disease

ozanimod
S1PR modulator
Area of Research: Crohn's Disease
Phase 3
deucravacitinib
TYK2 inhibitor
Area of Research: Crohn's Disease
Phase 2
Expand All Displaying 5 of 11

Crohn’s Disease

No trials are available at this time. Check back for updates.

Eosinophilic Esophagitis

cendakimab
anti–IL-13
Area of Research: Eosinophilic Esophagitis
Phase 3
Expand All Displaying 5 of 11

Eosinophilic Esophagitis

No trials are available at this time. Check back for updates.

Idiopathic Inflammatory Myopathy

Expand All Displaying 5 of 11

Idiopathic Inflammatory Myopathy

No trials are available at this time. Check back for updates.

Lupus Nephritis

deucravacitinib
TYK2 inhibitor
Area of Research: Lupus Nephritis
Phase 2
Expand All Displaying 5 of 11

Lupus Nephritis

No trials are available at this time. Check back for updates.

Multiple Sclerosis

ozanimod
S1PR modulator
Area of Research: Multiple Sclerosis
Phase 3
Expand All Displaying 5 of 11

Multiple Sclerosis

No trials are available at this time. Check back for updates.

Psoriasis

deucravacitinib
TYK2 inhibitor
Area of Research: Psoriasis
Phase 3
Expand All Displaying 5 of 11

Psoriasis

No trials are available at this time. Check back for updates.

Psoriatic Arthritis

Expand All Displaying 5 of 11

Psoriatic Arthritis

No trials are available at this time. Check back for updates.

Renal Transplant

Expand All Displaying 5 of 11

Renal Transplant

No trials are available at this time. Check back for updates.

Rheumatoid Arthritis

abatacept
Immunomodulatory agent
Area of Research: Rheumatoid Arthritis
Phase 2
Expand All Displaying 5 of 11

Rheumatoid Arthritis

No trials are available at this time. Check back for updates.

Sjögren’s Syndrome

branebrutinib
BTK inhibitor
Area of Research: Sjögren's Syndrome
Phase 2
Expand All Displaying 5 of 11

Sjögren’s Syndrome

No trials are available at this time. Check back for updates.

Systemic Lupus Erythematosus

branebrutinib
BTK inhibitor
Area of Research: Systemic Lupus Erythematosus
Phase 2
deucravacitinib
TYK2 inhibitor
Area of Research: Systemic Lupus Erythematosus
Phase 2
Expand All Displaying 5 of 11

Systemic Lupus Erythematosus

No trials are available at this time. Check back for updates.

Ulcerative Colitis

deucravacitinib
TYK2 inhibitor
Area of Research: Ulcerative Colitis
Phase 2
Expand All Displaying 5 of 11

Ulcerative Colitis

No trials are available at this time. Check back for updates.

Neuroscience (General)

Expand All Displaying 5 of 11

Neuroscience (General)

No trials are available at this time. Check back for updates.

Bladder

nivolumab
anti–PD-1
Area of Research: BCG R/R HR NMIBC
Phase 3
nivolumab + chemo ± linrodostat mesylate
anti–PD-1 + chemo ± IDO1 inhibitor
Area of Research: Peri-operative MIBC
Phase 3
nivolumab + ipilimumab or chemo
anti–PD-1 + anti–CTLA-4
Area of Research: 1L unresectable or metastatic urothelial carcinoma
Phase 3
nivolumab ± bempegaldesleukin
anti–PD-1 ± CD-122-biased preferential IL-2 receptor pathway agonist
Area of Research: Peri-operative MIBC
Phase 3
nivolumab + linrodostat mesylate ± BCG
anti–PD-1 + IDO1 inhibitor ± BCG
Area of Research: BCG R/R HR NMIBC
Phase 2
nivolumab ± BCG
anti–PD-1 ± BCG
Area of Research: BCG R/R HR NMIBC
Phase 2
Expand All Displaying 5 of 11

Bladder

No trials are available at this time. Check back for updates.

Breast

nivolumab + chemo followed by nivolumab + endocrine therapy
anti–PD-1
Area of Research: Neoadjuvant/adjuvant high-risk breast cancer
Phase 3
nivolumab + nab-paclitaxel ± ipilimumab
anti–PD1 + albumin-bound microtubule inhibitor ± CTLA-4
Area of Research: Advanced ER+/HER2-
Phase 1
nivolumab + nab-paclitaxel ± ipilimumab
anti–PD-1 + chemotherapy ± anti–CTLA-4
Area of Research: ER+/HER2- Advanced Breast Cancer
Phase 1
Expand All Displaying 5 of 11

Breast

No trials are available at this time. Check back for updates.

Colorectal

nivolumab ± ipilimumab
anti–PD-1 ± anti–CTLA-4
Area of Research: 1L+ recurrent or metastatic MSI-H/dMMR CRC
Phase 3
Expand All Displaying 5 of 11

Colorectal

No trials are available at this time. Check back for updates.

Esophageal, Gastroesophageal

ipilimumab + rucaparib
anti–CTLA-4 + PARP inhibitor
Area of Research: 2L+ inoperable, advanced, or metastatic EC, GC, or GEJ carcinoma
Phase 2
nivolumab + ipilimumab
anti–PD-1 + anti–CTLA-4
Area of Research: 2L+ inoperable, advanced, or metastatic EC, GC, or GEJ carcinoma
Phase 2
nivolumab + ipilimumab + rucaparib
anti–PD-1 + anti–CTLA-4 + PARP inhibitor
Area of Research: 2L+ inoperable, advanced, or metastatic EC, GC, or GEJ carcinoma
Phase 2
nivolumab + linrodostat mesylate
anti–PD-1 + IDO1 inhibitor
Area of Research: 2L+ inoperable, advanced, or metastatic EC, GC, or GEJ carcinoma
Phase 2
nivolumab + relatlimab
anti–PD-1 + anti–LAG-3
Area of Research: 2L+ inoperable, advanced, or metastatic EC, GC, or GEJ carcinoma
Phase 2
nivolumab + rucaparib
anti–PD-1 + PARP inhibitor
Area of Research: 2L+ inoperable, advanced, or metastatic EC, GC, or GEJ carcinoma
Phase 2
Expand All Displaying 5 of 11

Esophageal, Gastroesophageal

No trials are available at this time. Check back for updates.

Gastric

ipilimumab + rucaparib
anti–CTLA-4 + PARP inhibitor
Area of Research: 2L+ inoperable, advanced, or metastatic EC, GC, or GEJ carcinoma
Phase 2
nivolumab + ipilimumab
anti–PD-1 + anti–CTLA-4
Area of Research: 2L+ inoperable, advanced, or metastatic EC, GC, or GEJ carcinoma
Phase 2
nivolumab + ipilimumab + rucaparib
anti–PD-1 + anti–CTLA-4 + PARP inhibitor
Area of Research: 2L+ inoperable, advanced, or metastatic EC, GC, or GEJ carcinoma
Phase 2
nivolumab + linrodostat mesylate
anti–PD-1 + IDO1 inhibitor
Area of Research: 2L+ inoperable, advanced, or metastatic EC, GC, or GEJ carcinoma
Phase 2
nivolumab + relatlimab
anti–PD-1 + anti–LAG-3
Area of Research: 2L+ inoperable, advanced, or metastatic EC, GC, or GEJ carcinoma
Phase 2
nivolumab + rucaparib
anti–PD-1 + PARP inhibitor
Area of Research: 2L+ inoperable, advanced, or metastatic EC, GC, or GEJ carcinoma
Phase 2
Expand All Displaying 5 of 11

Gastric

No trials are available at this time. Check back for updates.

Glioblastoma

CC-90010 + chemo
BET inhibitor
Area of Research: Newly diagnosed glioblastoma
Phase 1/2
Expand All Displaying 5 of 11

Glioblastoma

No trials are available at this time. Check back for updates.

Head & Neck

nivolumab ± motolimod
anti–PD-1 ± TLR-8
Area of Research: Solid Tumors
Phase 1
Expand All Displaying 5 of 11

Head & Neck

No trials are available at this time. Check back for updates.

Hepatocellular Carcinoma

nivolumab + ipilimumab
anti–PD-1 + anti–CTLA-4
Area of Research: 1L advanced HCC
Phase 3
nivolumab + TACE ± ipilimumab
anti–PD-1 + TACE ± anti–CTLA-4
Area of Research: Intermediate stage HCC
Phase 3
Expand All Displaying 5 of 11

Hepatocellular Carcinoma

No trials are available at this time. Check back for updates.

Lung Cancer

Neoadjuvant nivolumab + chemo, followed by adjuvant nivolumab
anti–PD-1
Area of Research: Resectable NSCLC (≥4 cm)
Phase 3
nivolumab + chemo
anti–PD-1 + chemotherapy
Area of Research: Stage IV or recurrent NSCLC
Phase 3
nivolumab + chemo + RT, followed by maintenance nivolumab ± ipilimumab
anti–PD-1 ± anti–CTLA-4
Area of Research: Locally advanced NSCLC amenable to cCRT
Phase 3
nivolumab ± ipilimumab
anti–PD-1 ± anti–CTLA-4
Area of Research: Stage IV or recurrent NSCLC
Phase 3
CC-90011 + nivolumab
LSD1 inhibitor + anti–PD-1
Area of Research: 1L/2L SCLC/sqNSCLC
Phase 2
nivolumab + chemo ± BMS-986012
anti–PD-1 + chemo ± anti–FucGM1
Area of Research: 1L ES-SCLC
Phase 2
nivolumab + chemo ± relatimab
anti–PD-1 + chemotherapy ± anti–LAG-3
Area of Research: 1L Stage IV or recurrent NSCLC
Phase 2
nivolumab + ipilimumab
anti–PD-1 + anti–CTLA-4
Area of Research: 1L mNSCLC
Phase 2
Expand All Displaying 5 of 11

Lung Cancer

No trials are available at this time. Check back for updates.

Melanoma

nivolumab
anti–PD-1
Area of Research: Adjuvant stage IIB/C melanoma
Phase 3
nivolumab ± bempegaldesleukin
anti–PD-1 ± CD-122-preferential IL-2 pathway agonist
Area of Research: 1L unresectable or metastatic melanoma
Phase 3
nivolumab ± bempegaldesleukin
anti–PD-1 ± CD-122-preferential IL-2 pathway agonist
Area of Research: Adjuvant fully resected melanoma in patients at high risk for recurrence
Phase 3
nivolumab
anti–PD-1
Area of Research: Post-resection of Stage IIIa/b/c/d or Stage IV Melanoma
Phase 1/2
nivolumab ± relatlimab
anti–PD-1 ± anti–LAG-3
Area of Research: Advanced or unresectable melanoma patients who have progressed on/after anti–PD-(L)1 therapy
Phase 1
Expand All Displaying 5 of 11

Melanoma

No trials are available at this time. Check back for updates.

Mesothelioma

Expand All Displaying 5 of 11

Mesothelioma

No trials are available at this time. Check back for updates.

Ovarian

Expand All Displaying 5 of 11

Ovarian

No trials are available at this time. Check back for updates.

Pan-Tumor TMB High

Expand All Displaying 5 of 11

Pan-Tumor TMB High

No trials are available at this time. Check back for updates.

Pancreatic Cancer

Expand All Displaying 5 of 11

Pancreatic Cancer

No trials are available at this time. Check back for updates.

Pediatric

Expand All Displaying 5 of 11

Pediatric

No trials are available at this time. Check back for updates.

Prostate

nivolumab + chemo + steroid
anti–PD-1
Area of Research: 2L+ mCRPC
Phase 3
ipilimumab ± nivolumab
anti–CTLA-4 ± anti–PD-1
Area of Research: 2L+ mCRPC
Phase 2
CC-90011+ anti-androgen + steroid
LSD1 Inhibitor + anti-androgen + steroid
Area of Research: Metastatic CRPC
Phase 1
CC-94676
AR-LDD
Area of Research: Metastatic CRPC
Phase 1
Expand All Displaying 5 of 11

Prostate

No trials are available at this time. Check back for updates.

Renal Cell Carcinoma

nivolumab
anti–PD-1
Area of Research: Advanced or mccRCC
Phase 3
nivolumab ± ipilimumab
anti–PD-1 ± anti–CTLA-4
Area of Research: Adjuvant RCC
Phase 3
nivolumab + cabozantinib ± bempegaldesleukin
anti–PD-1 + TKI ± CD-122-preferential IL-2 pathway agonist
Area of Research: Advanced or mRCC
Phase 1/2
nivolumab + ipilimumab
anti–PD-1 + anti–CTLA-4
Area of Research: Advanced RCC
Phase 2
nivolumab + TKI + bempegaldesleukin
anti–PD-1 + TKI + CD-122-preferential IL-2 pathway agonist
Area of Research: Advanced or mRCC
Phase 1/2
Expand All Displaying 5 of 11

Renal Cell Carcinoma

No trials are available at this time. Check back for updates.

Solid Tumors (General)

BMS-986315 ± nivolumab
anti–NKG2A ± anti–PD-1
Area of Research: Advanced Solid Tumors
Phase 1/2
relatlimab + nivolumab + BMS-986205
anti–LAG-3 + anti–PD-1 + IDO1 Inhibitor
Area of Research: Advanced Solid Tumors
Phase 1/2
nivolumab ± relatlimab
anti–PD-1 ± anti–LAG-3
Area of Research: Advanced Solid Tumors
Phase 1/2
Phase 1
nivolumab ± ipilimumab
anti–PD-1 ± anti–CTLA-4
Area of Research: TMB-H advanced or metastatic solid tumors
Phase 2
nivolumab ± hyaluronidase
anti–PD-1 ± hyaluronidase
Area of Research: Advanced or metastatic solid tumors
Phase 1/2
nivolumab + MEK inhibitor ± ipilimumab
anti–PD-1 + MEK inhibitor ± anti–CTLA-4
Area of Research: 2L+ mCRC
Phase 1/2
nivolumab + bempegaldesleukin
anti–PD-1 + CD-122-preferential IL-2 pathway agonist
Area of Research: Children, adolescents, and young adults with R/R malignancies
Phase 1/2
nivolumab
anti–PD-1
Area of Research: Pan-Tumor Study for Long Term Follow-up
Phase 2
BMS-986415 ± nivolumab
IL-2 Fc ± anti–PD-1
Area of Research: Advanced Solid Tumors
Phase 1/2
relatlimab + nivolumab + ipilimumab
anti–LAG-3 + anti–PD-1 + anti–CTLA-4
Area of Research: Advanced Solid Tumors
Phase 1/2
BMS-986249 ± nivolumab
anti–CTLA-4 ProbodyTM ± anti–PD-1
Area of Research: Advanced Solid Tumors
Phase 1/2
BMS-986178 + nivolumab + ipilimumab
anti–OX40 + anti–PD-1 + anti–CTLA-4
Area of Research: Advanced Solid Tumors
Phase 1/2
BMS-986178 + nivolumab + vaccine ± chemo
anti–OX40 + anti–PD1 + vaccine ± chemo
Area of Research: Advanced Solid Tumors
Phase 1/2
BMS-986178 ± ipilimumab
anti–OX40 ± anti–CTLA-4
Area of Research: Advanced Solid Tumors
Phase 1/2
BMS-986178 ± nivolumab
anti–OX40 ± anti–PD-1
Area of Research: Advanced Solid Tumors
Phase 1/2
BMS-986288 + nivolumab
anti–CTLA-4–NF ProbodyTM + anti–PD-1
Area of Research: Advanced Solid Tumors
Phase 1/2
BMS-986258 ± hyaluronidase
anti–TIM-3
Area of Research: Advanced Solid Tumors
Phase 1/2
BMS-986253 + nivolumab
anti–IL-8 ± anti–PD-1
Area of Research: Advanced Solid Tumors
Phase 1/2
BMS-986218
anti–CTLA-4–NF
Area of Research: Advanced Solid Tumors
Phase 1/2
nivolumab + relatlimab
anti–PD-1 + anti–LAG-3
Area of Research: Advanced Solid Tumors
Phase 1
nivolumab + linrodostat mesylate
anti–PD-1 ± IDO1 inhibitor
Area of Research: Advanced Solid Tumors
Phase 1
nivolumab + cabiralizumab
anti–PD-1 + anti–CSF1
Area of Research: Advanced Solid Tumors
Phase 1
nivolumab + ipilimumab
anti–PD-1 ± anti–LAG-3
Area of Research: Advanced Solid Tumors
Phase 1
BMS-986301
STING agonist
Area of Research: Advanced Solid Tumors
Phase 1
nivolumab + BMS-986205
anti–PD-1 + IDO1 Inhibitor
Area of Research: Advanced Solid Tumors
Phase 1
CC-95251
anti–SIRPα
Area of Research: Solid tumors
Phase 1
BMS-986299
NLRP3 agonist
Area of Research: Advanced Solid Tumors
Phase 1
CC-90010
BET inhibitor
Area of Research: Solid tumors
Phase 1
CC-90011
LSD1 inhibitor
Area of Research: Advanced Solid Tumors
Phase 1
Expand All Displaying 5 of 11

Solid Tumors (General)

No trials are available at this time. Check back for updates.

= Development partnerships include:

  • ELIQUIS: Pfizer
  • BMS-986177, BMS-986209: Janssen
  • BMS-986263: Nitto Denko
  • REBLOZYL: Acceleron Pharma
  • Bempegaldesleukin: Nektar
  • YERVOY, OPDIVO, Relatlimab: Ono
  • TRPH-222: TriPhase Accelerator
  • ABECMA, bb21217: licensed from bluebird bio®
  • RUBRACA: Clovis Oncology
  • COMETRIQ, CABOMETYX: Exelixis
  • BMS-986415: Dragonfly